Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma

Melanoma is one of the most aggressive forms of skin cancer, representing only 5% of all skin cancer but 80% of all death by skin cancer. Diagnosis and treatment of melanoma must be early because prognosis depends on stage disease.Immunotherapy is used in metastatic melanoma. However, all patients not respond to immunotherapy.Helioderma (photoaging) is a marker of exposure to UV rays and therefore of mutagenesis. Thus, helioderma could be associated with the response to immunotherapy.

Inclusion Criteria:metastatic melanomaWhatever the mutation BRAF statustreated by immunotherapy or specific therapyaged more than 18agreeing to participate to the studyExclusion Criteria:Patient whose treatment by immunotherapy has already startedPatient who have had a radiotherapy or chemotherapy treatmentPatient with an unknown primary melanoma, choroidal melanomaPatient with other cancer (except basal cell and squamous cell skin cancer)Patient with genetic predisposition for melanomaaged less than 18Adult not agreeing to participate to the study